TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC

Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors

Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

In Brief for June 22, 2022

Journal of Thoracic Oncology Impact Factor Surpasses 20

Step It Up For Research!

Foundation Announces 2022 Young Investigator Grant Recipients

Workshops Offer Opportunities for Education, Networking Based on Shared Interests, Specialties

WCLC Chairs Welcome Opportunity to Gather Face-to-Face

Virtual Program Brings WCLC to Attendees Worldwide